Dr. Massod Rahimi is a product quality assessor with the Office of Biotechnology Products (OBP) in the Office of Pharmaceutical Quality (OPQ) at the Center for Drug Evaluation and Research (CDER)/U.S. Food and Drug Administration (FDA). Dr. Rahimi received his B.S. degree in Biology and Psychology from the University of Maryland, Baltimore County and his M.S. and Ph.D. degrees in Tumor Biology from Georgetown University. He completed a post-doctoral fellowship at the National Cancer Institute (NCI) in 2012 before becoming a NCI/FDA Interagency Oncology Task Force (IOTF) fellow. In 2014 Dr. Rahimi became a Senior Staff Fellow – Research/Reviewer in OBP where he divided his time between investigating cellular processes in the production and regulation of growth and developmental factors and conducting product quality assessments for biotechnology products.
In his current position, Dr. Rahimi manages a portfolio of Investigational New Drug (IND) and Biologics License Application (BLA) submissions for biotechnology products including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, therapeutic proteins, and biosimilars. He conducts product quality assessments and manufacturing facility inspections for biotechnology products in his portfolio.